Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

doi:10.3748/wjg.v31.i24.108298

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1488)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-7) series.

Item

Count

PDF

HTML

664

Figures (1-7)

141

Tables (1-7)

Sum=909

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

100

Download

286

Sum=386

Publishing Process of This Article

Item

Count

Browse

Download

122

Sum=146

Jun 28, 2025 (publication date) through Jul 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jun 28, 2025; 31(24): 108298
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.108298

Full Size Figure Download Figure

Figure 2 After propensity score-matching analysis of progression-free survival and overall survival. A: After propensity score-matching analysis of progression-free survival (ratio = 4); B: After propensity score-matching analysis of overall survival (ratio = 4).

Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(24): 108298
URL: https://www.wjgnet.com/1007-9327/full/v31/i24/108298.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i24.108298